ExThera Medical Release: Study at the Karolinska Institute Suggests Potential for Reducing the High Death Rate from Sepsis, one of the Top-10 Causes of Death in the U.S.
BERKELEY, Calif.--(BUSINESS WIRE)--ExThera Medical announced today that the results of a preliminary study (“Cytokines in blood from septic patients interact with surface immobilized heparin”) of its proprietary medical device, Seraph™ extracorporeal affinity therapy, have been published in the current issue of the Journal of the American Society for Artificial Organs (Jan.-Feb. 2010).